AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reissued by stock analysts at Deutsche Bank AG in a research note issued on Friday, July 28th, Marketbeat.com reports. They presently have a GBX 5,700 ($75.19) price target on the biopharmaceutical company’s stock. Deutsche Bank AG’s target price indicates a potential upside of 25.72% from the company’s current price.
Several other research analysts have also issued reports on the company. Citigroup Inc. reaffirmed a “buy” rating and set a GBX 6,000 ($79.15) target price on shares of AstraZeneca plc in a research report on Thursday, July 13th. Barclays PLC reaffirmed an “overweight” rating and set a GBX 6,000 ($79.15) target price on shares of AstraZeneca plc in a research report on Friday, April 28th. HSBC Holdings plc lowered AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($59.36) target price for the company. in a research report on Tuesday, July 4th. Jefferies Group LLC lowered their target price on AstraZeneca plc from GBX 5,500 ($72.55) to GBX 5,300 ($69.91) and set a “hold” rating for the company in a research report on Wednesday, July 12th. Finally, Shore Capital reissued a “sell” rating on shares of AstraZeneca plc in a research report on Thursday, April 27th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company. AstraZeneca plc presently has a consensus rating of “Hold” and a consensus price target of GBX 4,956.48 ($65.38).
AstraZeneca plc (LON AZN) traded down 0.08% during midday trading on Friday, hitting GBX 4530.50. The stock had a trading volume of 1,221,574 shares. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The company’s market capitalization is GBX 57.36 billion. The company’s 50-day moving average price is GBX 5,101.58 and its 200 day moving average price is GBX 4,861.19.
In other news, insider Nazneen Rahman purchased 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The stock was purchased at an average cost of GBX 4,370 ($57.64) per share, for a total transaction of £1,704.30 ($2,248.12).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.
